Cirio advises Annexin in connection with its rights issue

Cirio Advokatbyrå AB advises Annexin Pharmaceuticals AB (publ), listed on Nasdaq First North Growth Market, in connection with its rights issue directed to the company’s existing shareholders.

An extraordinary general meeting will be held on 28 January 2020 to resolve on the rights issue. The share issue is fully secured through subscription and underwriting commitments.

A prospectus will be prepared in connection with the rights issue and is expected to be published on or around 4 February 2020.

Annexin is a world-leading biotechnology company in the Annexin A5 field, for treatment of various cardiovascular diseases, which today is the most common cause of death. The company is listed on the Nasdaq First North Growth Market.

Cirio advises Annexin with a team headed by Per Hedman (Life science and Mergers & Acquisitions) and Maria Arnoldsson (Equity Capital Markets and Public M&A) together with Oscar Lunde and Erik Ejdersjö (Equity Capital Markets and Public M&A), and Jessika Lagebro (Mergers & Acquisitions).

For more information, please contact: